title: Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients.
abstract: BACKGROUND
  The concentration of heart-type fatty acid-binding protein (hFABP), a promising novel marker for detection of acute or persistent myocardial damage, is significantly influenced by renal clearance and thus has limitations to its usefulness in patients with renal dysfunction. We evaluated whether the serum ratio of hFABP to myoglobin (F/M) might be a useful marker for assessing cardiac damage in hemodialysis patients.
  
  
  METHODS
  Serum hFABP and myoglobin were measured, and the value of F/M was calculated in 21 hemodialysis patients. Cardiac markers (cardiac troponin T [cTnT], atrial natriuretic peptide [ANP], and brain natriuretic peptide [BNP]) and echocardiographic indices (left ventricular end-diastolic dimension [LVDd], left ventricular mass index [LVMI], and inferior vena cava [IVC] dimension) were examined and compared with hFABP, myoglobin, and F/M ratios.
  
  
  RESULTS
  Serum hFABP and myoglobin levels were significantly elevated in hemodialysis patients and reduced by 30-40% during hemodialysis. The value of F/M after hemodialysis, but not the concentration of hFABP or myoglobin, had significant linear correlations with ANP, BNP, cTnT, LVDd, LVMI, and IVC.
  
  
  CONCLUSIONS
  The value of F/M after hemodialysis, but not the concentration of hFABP itself, might be a newly useful marker for estimation of cardiac damage and volume overload in hemodialysis patients.
authors.affiliation: Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. furuhasi@sapmed.ac.jp
authors.forename: Masato
authors.initials: M
authors.lastname: Furuhashi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ura
authors.forename: Koichi
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Hideaki
authors.initials: H
authors.lastname: Yoshida
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Tsuchihashi
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Nakata
authors.forename: Kaxuaki
authors.initials: K
authors.lastname: Shimamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D009320:Atrial Natriuretic Factor / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis* / Q000209:etiology*; D002352:Carrier Proteins / Q000097:blood*; D004452:Echocardiography; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009211:Myoglobin / Q000097:blood*; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009363:Neoplasm Proteins; D006435:Renal Dialysis / Q000009:adverse effects*; D020107:Troponin T / Q000097:blood; D025521:Tumor Suppressor Proteins; D014682:Vena Cava, Inferior / Q000000981:diagnostic imaging
chemical_list: D015415:Biomarkers; D002352:Carrier Proteins; C107608:FABP7 protein, human; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D009211:Myoglobin; D009363:Neoplasm Proteins; D020107:Troponin T; D025521:Tumor Suppressor Proteins; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor